NCT02526368View on ClinicalTrials.gov

Pilot Study of (MR) Imaging with Pyruvate (13C) to Detect High Grade Prostate Cancer

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

March 22, 2016

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Prostate CancerLocalized Prostate Carcinoma
Interventions
DRUG

Hyperpolarized 13C-Pyruvate

Given IV

DRUG

Hyperpolarized 13C,15N2-urea

Given IV

PROCEDURE

Magnetic Resonance Spectroscopic Imaging

Undergo MRSI

Trial Locations (1)

94143

RECRUITING

University of California, San Francisco, San Francisco

All Listed Sponsors
collaborator

American Cancer Society, Inc.

OTHER

collaborator

National Cancer Institute (NCI)

NIH

collaborator

National Institute for Biomedical Imaging and Bioengineering (NIBIB)

NIH

lead

Ivan de Kouchkovsky, MD

OTHER